Kimberly Vanover
SVP, Early Stage Clinical Development and Translat
Intra-Cellular Therapies

Dr. Vanover is Senior Vice President ofEarly Stage Clinical Development and Translational Medicine at Intra-Cellular Therapies. With over 25 years in the biopharmaceutical industry, she has led the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases, including work in the areas of schizophrenia, bipolar disorder, and dementia. Prior to joining Intra-Cellular Therapies in 2007, Dr. Vanover held various positions at ACADIA Pharmaceuticals and CoCensys and participated in the discovery and development of a broad range of new CNS therapeutics, including drugs to treat psychosis, insomnia, cognitive impairment, movement disorders, acute and neuropathic pain, anxiety, epilepsy, and drug abuse. She also participated in the discovery and development of Nuplazid, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Vanover received Postdoctoral training at Lederle Laboratories and in the Department of Psychiatry at the University of California, San Diego. Dr. Vanover received her B.A. in Psychology from the University of Missouri and her Ph.D. in Biopsychology from the University of Chicago.